Christophe Tournigand

Christophe Tournigand

Auto-generated profile, based on publicly available information

Christophe Tournigand

Department of Medical Oncology, AP-HP, Henri-Mondor Hospital, Créteil, France

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2011 in Nature Medicine
Verified
Journal Article
Closed access
CDCoralie Dorard
Coralie Dorard
ATAurélie de Thonel
Aurélie de Thonel
ACAda Collura
Ada Collura
LMLaetitia Marisa
Laetitia Marisa
MSMagali Svrcek
Magali Svrcek
ADAlex Duval
Alex Duval

1 January 2008 in International Journal of Medical Sciences
Verified
Journal Article
Open access
ADArmelle Dufresne
Armelle Dufresne
XPXavier. Pivot
Xavier. Pivot
CTChristophe Tournigand
Christophe Tournigand
TFThomas Facchini
Thomas Facchini
TAThierry Alweeg
Thierry Alweeg
AGAimery De Gramont
Aimery De Gramont
The present study was conducted in patients with metastatic breast cancer. Its aim was to identify the factors which influence progression -free survival (PFS) and overall survival (OS) after the first line of chemotherapy in patients with positive tumour hormone receptor status. The patients with early disease progression during first-line chemotherapy were not included. In total, 560 patients who achieved a stable disease or a response to first-line chemotherapy were studied. The factors identified to improve the duration of PFS or OS in multivariate analysis were: number of metastatic sites (p = .01; p = .01), metastatic sites (p = .02; p = .04), Disease free interval (p = .001; p < .0001), previous hormonal therapy (p = .03; p = ns), response to first line chemotherapy (p < .0001; p = 0.0001) and an administration of maintenance hormonal therapy (p < .0001; p = .001). The major impact obtained by maintenance hormonal treatment after first-line chemotherapy in this study seems to indicate that this strategy should be recommended in patients with an ER or PgR positive tumour.

13 September 2011 in Nature Reviews Clinical Oncology
Verified
Journal Article
Closed access
CTChristophe Tournigand
Christophe Tournigand
AGAimery de Gramont
Aimery de Gramont

1 January 2006 in Cancer Investigation
Verified
Journal Article
Closed access
MHMohamed Hebbar
Mohamed Hebbar
CTChristophe Tournigand
Christophe Tournigand
GLGérard Lledo
Gérard Lledo
MMMay Mabro
May Mabro
TAThierry André
Thierry André
O(Oncology Multidisciplinary Research Group (GERCOR)
Oncology Multidisciplinary Research Group (GERCOR)
We assessed a schedule alternating 4 FOLFOX and 4 FOLFIRI cycles in 39 patients with 5-FU resistant metastatic colorectal cancer. Patients alternatively received 4 FOLFOX-6 cycles (oxaliplatin 100 mg/m2, leucovorin 200 mg/m2 d1 followed by bolus 400 mg/m2 5-FU and by a 46-hour 2,400 mg/m2 5-FU infusion, every 2 weeks), and 4 FOLFIRI cycles (oxaliplatin replaced by irinotecan 180 mg/m2 d1) until progression or limiting toxicity. Eigteen patients achieved an objective response (46.1 percent). Median progression-free and overall survivals were 8.8 and 18.7 months, respectively. Only 2 patients (5.1 percent) had Grade 3 oxaliplatin-related sensory-neuropathy. This schedule had so promising efficacy and safety.

20 February 2017 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
FSFlorian Scotte
Florian Scotte
CHChristian Hervé
Christian Hervé
PLPauline Leroy
Pauline Leroy
JTJean-Marc Tourani
Jean-Marc Tourani
RBRené-Jean BENSADOUN
René-Jean BENSADOUN
IKIvan Krakowski
Ivan Krakowski

11 December 2023 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
AHAnne Hulin
Anne Hulin
TGThibaut Gelé
Thibaut Gelé
CFCharlotte Fenioux
Charlotte Fenioux
EKEmmanuelle Kempf
Emmanuelle Kempf
DSDil Sahali
Dil Sahali
Mario OlleroMario Ollero
Mario Ollero
Tyrosine kinase inhibitors (TKI) have introduced a significant advancement in cancer management. These compounds are administered orally, and their absorption holds a pivotal role in determining their variable efficacy. They exhibit extensive distribution within the body, binding strongly to both plasma and tissue proteins. Often reliant on efflux and influx transporters, TKI undergo primary metabolism by intestinal and hepatic cytochrome P450 enzymes, with nonkidney clearance being predominant. Owing to their limited therapeutic window, many TKI display considerable intraindividual and interindividual variability. This review offers a comprehensive analysis of the clinical pharmacokinetics of TKI, detailing their interactions with drug transporters and metabolic enzymes, while discussing potential clinical implications. The prevalence of kidney conditions, such as AKI and CKD, among patients with cancer is explored in their effect on TKI pharmacokinetics. Finally, the potential nephrotoxicity associated with TKI is also examined.